Resurrect Bio

General InformationResurrect Bio appears to be a clean-tech company focused on biological or genetic restoration, though limited public information is available about their current operations, location, or team size.

Funding & FinancialsNo confirmed funding information is publicly available for Resurrect Bio at this time.

Leadership & TeamLeadership and team composition details for Resurrect Bio could not be verified from available sources.

Recent ActivityCurrent product developments, launches, or partnerships for Resurrect Bio are not documented in accessible public records.

Highlights

Total Raised

—

3 rounds

Latest Round

$10.3

May 19, 2026

Stage

—

clean-tech

Employees

—

Headquarters

—

News Coverage

1 articles

Last: 13d ago

Talent Signals

—

SEC Filings

—

Backers

AgFunder

Calculus Capital

Corteva Catalyst

Corteva (via Catalyst platform)

Pymwymic

SynBioVen

UKI2S

Funding History

$8.1

2026

Series A

$8.1

2026

Series A

$10.3

2026

Series A (final close)

SEC Form D Editorial

May 19, 2026

$10.3 millionSeries A (final close) · Editorial

Investors: Corteva (via Catalyst platform), Calculus Capital, Pymwymic, UKI2S, SynBioVen, AgFunder

Resurrect Bio closed an oversubscribed €8.8M ($10.3M) Series A led by Corteva to scale AI-powered gene editing that reactivates dormant disease-resistance genes in crops, with concurrent joint development agreement on corn disease resistance.

View article →

Apr 19, 2026

$8.1 millionSeries A · Editorial

Investors: Corteva Catalyst

Gene editing biotech startup Resurrect Bio closed Series A with $8.1 million led by Corteva Catalyst for sustainable crop protection.

Apr 2, 2026

$8.1 millionSeries A · Editorial

Investors: Corteva Catalyst

London-based Resurrect Bio announced the initial close of its Series A round with $8.1 million in funding led by Corteva Catalyst, developing gene editing capabilities for sustainable crop protection.

News Coverage 1

Clean13d ago

Corteva backs crop immunity startup with $10.3M oversubscribed round

Resurrect Bio closes Series A at €8.8M led by Corteva, betting on AI-powered gene editing to reactivate dormant disease resistance and displace chemical pesticides in commercial crop pipelines.

Similar Companies 6

CITY OF ST CLOUD NATIONAL SEPTEMBER 11 MEMORIAL AND MUSEUM AT THE WORLD TRADE CENTER TEXAS A&M ENGINEERING EXPERIMENT STATIONGrowth PHERONYM INC SEEDLING BIOSYSTEMS INC.INVASIVE SPECIES CORPORATION